Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 45

1.

Association between features of patient-provider discussions and routine prostate-specific antigen testing.

Liao JM, Ommerborn MJ, Clark CR.

PLoS One. 2017 May 16;12(5):e0177687. doi: 10.1371/journal.pone.0177687. eCollection 2017.

2.

Factors influencing Nigerian men's decision to undergo prostate specific antigen testing.

Enaworu OU, Khutan R.

Afr Health Sci. 2016 Jun;16(2):524-32. doi: 10.4314/ahs.v16i2.21.

3.

Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.

Gnanapragasam VJ, Lophatananon A, Wright KA, Muir KR, Gavin A, Greenberg DC.

PLoS Med. 2016 Aug 2;13(8):e1002063. doi: 10.1371/journal.pmed.1002063. eCollection 2016 Aug.

4.

The Role of Personalised Choice in Decision Support: A Randomized Controlled Trial of an Online Decision Aid for Prostate Cancer Screening.

Salkeld G, Cunich M, Dowie J, Howard K, Patel MI, Mann G, Lipworth W.

PLoS One. 2016 Apr 6;11(4):e0152999. doi: 10.1371/journal.pone.0152999. eCollection 2016.

5.

Involving a Citizens' Jury in Decisions on Individual Screening for Prostate Cancer.

Mosconi P, Colombo C, Satolli R, Carzaniga S; Steering Committee; Scientific Committee.

PLoS One. 2016 Jan 11;11(1):e0143176. doi: 10.1371/journal.pone.0143176. eCollection 2016.

6.

Pre-screening Discussions and Prostate-Specific Antigen Testing for Prostate Cancer Screening.

Li J, Zhao G, Hall IJ.

Am J Prev Med. 2015 Aug;49(2):259-63. doi: 10.1016/j.amepre.2015.02.007. Epub 2015 May 18.

7.

Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.

Stattin P, Vickers AJ, Sjoberg DD, Johansson R, Granfors T, Johansson M, Pettersson K, Scardino PT, Hallmans G, Lilja H.

Eur Urol. 2015 Aug;68(2):207-13. doi: 10.1016/j.eururo.2015.01.009. Epub 2015 Feb 11.

8.

A Randomized Controlled Effectiveness Trial for PSA Screening Decision Support Interventions in Two Primary Care Settings.

Lewis CL, Adams J, Tai-Seale M, Huang Q, Knowles SB, Nielsen ME, Pignone MP, Walter LC, Frosch DL.

J Gen Intern Med. 2015 Jun;30(6):810-6. doi: 10.1007/s11606-015-3214-9. Epub 2015 Feb 10.

9.

Deliberative democracy and cancer screening consent: a randomised control trial of the effect of a community jury on men's knowledge about and intentions to participate in PSA screening.

Thomas R, Glasziou P, Rychetnik L, Mackenzie G, Gardiner R, Doust J.

BMJ Open. 2014 Dec 24;4(12):e005691. doi: 10.1136/bmjopen-2014-005691.

10.

Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.

Brockman JA, Alanee S, Vickers AJ, Scardino PT, Wood DP, Kibel AS, Lin DW, Bianco FJ Jr, Rabah DM, Klein EA, Ciezki JP, Gao T, Kattan MW, Stephenson AJ.

Eur Urol. 2015 Jun;67(6):1160-1167. doi: 10.1016/j.eururo.2014.09.019. Epub 2014 Oct 6.

11.

Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.

Nordström T, Vickers A, Assel M, Lilja H, Grönberg H, Eklund M.

Eur Urol. 2015 Jul;68(1):139-46. doi: 10.1016/j.eururo.2014.08.010. Epub 2014 Aug 20.

12.

African american primary care physicians' prostate cancer screening practices.

Ross LE, Hall IJ.

J Prim Care Community Health. 2014 Jan 1;5(1):36-43. doi: 10.1177/2150131913507454. Epub 2013 Oct 17.

13.

Prostate specific antigen testing in family practice: a cross sectional survey of self-reported rates of and reasons for testing participation and risk disclosure.

Carey M, Bryant J, Yoong SL, Russell G, Barker D, Sanson-Fisher R.

BMC Fam Pract. 2013 Dec 9;14:186. doi: 10.1186/1471-2296-14-186.

14.

Interdisciplinary decision making in prostate cancer therapy - 5-years' time trends at the Interdisciplinary Prostate Cancer Center (IPC) of the Charité Berlin.

Baumunk D, Reunkoff R, Kushner J, Baumunk A, Kempkensteffen C, Steiner U, Weikert S, Moser L, Schrader M, Höcht S, Wiegel T, Miller K, Schostak M.

BMC Med Inform Decis Mak. 2013 Aug 5;13:83. doi: 10.1186/1472-6947-13-83.

15.

Pairing physician education with patient activation to improve shared decisions in prostate cancer screening: a cluster randomized controlled trial.

Wilkes MS, Day FC, Srinivasan M, Griffin E, Tancredi DJ, Rainwater JA, Kravitz RL, Bell DS, Hoffman JR.

Ann Fam Med. 2013 Jul-Aug;11(4):324-34. doi: 10.1370/afm.1550.

16.

Physician communication regarding prostate cancer screening: analysis of unannounced standardized patient visits.

Feng B, Srinivasan M, Hoffman JR, Rainwater JA, Griffin E, Dragojevic M, Day FC, Wilkes MS.

Ann Fam Med. 2013 Jul-Aug;11(4):315-23. doi: 10.1370/afm.1509.

17.

National evidence on the use of shared decision making in prostate-specific antigen screening.

Han PK, Kobrin S, Breen N, Joseph DA, Li J, Frosch DL, Klabunde CN.

Ann Fam Med. 2013 Jul-Aug;11(4):306-14. doi: 10.1370/afm.1539.

18.

Five-year downstream outcomes following prostate-specific antigen screening in older men.

Walter LC, Fung KZ, Kirby KA, Shi Y, Espaldon R, O'Brien S, Freedland SJ, Powell AA, Hoffman RM.

JAMA Intern Med. 2013 May 27;173(10):866-73. doi: 10.1001/jamainternmed.2013.323.

19.

Development and validation of a 32-gene prognostic index for prostate cancer progression.

Wu CL, Schroeder BE, Ma XJ, Cutie CJ, Wu S, Salunga R, Zhang Y, Kattan MW, Schnabel CA, Erlander MG, McDougal WS.

Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6121-6. doi: 10.1073/pnas.1215870110. Epub 2013 Mar 26.

20.

Comparing 3 techniques for eliciting patient values for decision making about prostate-specific antigen screening: a randomized controlled trial.

Pignone MP, Howard K, Brenner AT, Crutchfield TM, Hawley ST, Lewis CL, Sheridan SL.

JAMA Intern Med. 2013 Mar 11;173(5):362-8. doi: 10.1001/jamainternmed.2013.2651.

Supplemental Content

Loading ...
Support Center